The future of cancer treatment — hailed as the “holy grail” of early detection — is now being put to the test.
Following a radically successful trial on cancer patients, a new blood test that promises to predict tumors more than a year before they begin to form is now being applied in hospitals across the United Kingdom.
“This is the first pan-cancer blood test,” said Ashish Tripathi, founder and CEO of Tzar Labs as well as chairman of Epigeneres Biotech, the Indian firm where the test was first developed in 2021. An updated report on their findings was published this month in the journal Stem Cells.
“We can detect [cancer] earlier than other known technologies … before the tumor has physically formed,” Tripathi continued during a new interview with author and medical advocate Deepak Chopra.
“Not only can I actually detect it at this stage — I can actually tell you which cancer and where it is forming, straight from a blood test.”
Read more at https://nypost.com/2023/03/27/holy-grail-of-cancer-detection-predicts-tumors-a-year-before-they-form-breakthrough/
#cancer #science #health
The New York Post is your source for breaking news, news about New York, sports, business, entertainment, opinion, real estate, culture, fashion, and more.
Subscribe to New York Post Sports: https://www.youtube.com/c/nypostsports
Catch the latest news here: https://nypost.com/
Follow The New York Post on:
Twitter – https://twitter.com/nypost
Facebook – https://www.facebook.com/NYPost